Long-term outcomes with pimavanserin for psychosis in clinical practice

Long-term outcomes with pimavanserin for psychosis in clinical practice

Introduction: Pimavanserin is the only medication FDA-approved for the treatment of Parkinson disease (PD) psychosis (PDP), but reports of long-term, real-world clinical experience are lacking. Methods: A retrospective chart review of all patients treated with pimavanserin was conducted at our large...

Full description

Bibliographic Details
Main Authors: Umer Akbar, Joseph H. Friedman
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Clinical Parkinsonism & Related Disorders
Subjects:
Parkinson disease
Dementia with Lewy body
Psychosis
Hallucinations
Delusions
Online Access:http://www.sciencedirect.com/science/article/pii/S2590112522000147

Similar Items

Similar Items